Login to Your Account

Other News To Note

Thursday, November 7, 2013
• Immunocore Ltd., of Oxford, UK, said it reached the first milestone in the multitarget research and licensing agreement with London-based Glaxosmithkline plc to develop immunotherapeutics based on its ImmTac monoclonal T-cell receptor technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription